Association Between Risk Factors and Medication Use Among Patients with Polycystic Ovary Syndrome at Kencana Clinic, Sorong City
Article Sidebar
Main Article Content
Page: 2801-2807
Abstract
Polycystic ovary syndrome (PCOS) requires individualized pharmacotherapy because reproductive and metabolic manifestations vary among patients. This study evaluated the associations of age, documented menstrual complaints, and pregnancy-related presentations with medication-count category among patients with PCOS at Kencana Clinic, Sorong City. A retrospective cross-sectional analysis was conducted on 118 eligible records selected by computer-generated simple random sampling from 412 records dated January 2022-December 2023. Associations were analyzed using the chi-square test and expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Patients aged >25 years were more likely to receive >2 medications than those aged ≤25 years (40/73 vs 16/45; OR = 2.197; 95% CI = 1.022-4.721; p = 0.042). Menstrual complaints and pregnancy-related presentations were not significantly associated with medication-count category (p = 0.297 for each comparison). Older age was associated with greater medication-count complexity, but did not establish causality. Treatment planning should integrate age with metabolic status, comorbidities, and reproductive goals.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. doi:10.3390/jcm12041454. DOI: https://doi.org/10.3390/jcm12041454
Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303-1314. doi:10.1007/s00404-024-07607-x. DOI: https://doi.org/10.1007/s00404-024-07607-x
Christie, Halimah E, Yohanes DC. Review artikel: Pengaruh metformin sebagai obat off-label untuk terapi pada wanita dengan polycystic ovary syndrome (PCOS). Farmaka. 2023;21:64-77.
Kesavan S, Chaudhry GS, Akim AM, Ranneh YK. The efficacy of metformin and exenatide in polycystic ovary syndrome (PCOS) patients. Ars Pharm. 2023;64(2):100-122. doi:10.30827/ars.v64i2.27302. DOI: https://doi.org/10.30827/ars.v64i2.27302
Yu JH, Moon MK, Ahn HC, Yang YM. Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: a retrospective study. Medicine (Baltimore). 2024;103(32):e39055. doi:10.1097/MD.0000000000039055. DOI: https://doi.org/10.1097/MD.0000000000039055
World Health Organization. Polycystic ovary syndrome [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Aug 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.
Zeng LH, Rana S, Hussain L, Asif M, Mehmood MH, Imran I, et al. Polycystic ovary syndrome: a disorder of reproductive age, its pathogenesis, and a discussion on the emerging role of herbal remedies. Front Pharmacol. 2022;13:874914. doi:10.3389/fphar.2022.874914. DOI: https://doi.org/10.3389/fphar.2022.874914
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24. doi:10.1093/humrep/der396. DOI: https://doi.org/10.1093/humrep/der396
Dason ES, Koshkina O, Chan C, Sobel M. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024;196(3):E85-E94. doi:10.1503/cmaj.231251. DOI: https://doi.org/10.1503/cmaj.231251
Legro R. Diagnosis and treatment of polycystic ovary syndrome (PCOS): an interview with Richard Legro. BMC Med. 2015;13:64. doi:10.1186/s12916-015-0299-2. DOI: https://doi.org/10.1186/s12916-015-0299-2
Ratnaningsih D, Siswatibudi H, Yogi Hernawan J. Gambaran terapi penggunaan obat pada wanita usia subur dengan masalah reproduksi PCOS (polycystic ovarian syndrome) di Yogyakarta. J Permata Indones. 2022;13(2):136-144. doi:10.59737/jpi.v13i2.172. DOI: https://doi.org/10.59737/jpi.v13i2.172
Kujanpää L, Arffman RK, Pesonen P, Hurskainen E, Järvelin MR, Franks S, et al. Polycystic ovary syndrome presents as a multimorbid condition by age 50: birth cohort linkage to national register data. Eur J Endocrinol. 2024;190(6):409-420. doi:10.1093/ejendo/lvae057. DOI: https://doi.org/10.1093/ejendo/lvae057
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran LJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. doi:10.1093/humrep/dey256. DOI: https://doi.org/10.1093/humrep/dey256
Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney LG, Teede HJ. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107(6):1380-1386.e1. doi:10.1016/j.fertnstert.2017.04.011. DOI: https://doi.org/10.1016/j.fertnstert.2017.04.011
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics. 2015;70(11):765-769. doi:10.6061/clinics/2015(11)09. DOI: https://doi.org/10.6061/clinics/2015(11)09
Peng G, Yan Z, Liu Y, Li J, Ma J, Tong N, et al. The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023;21(1):24. doi:10.1186/s12958-023-01075-9. DOI: https://doi.org/10.1186/s12958-023-01075-9
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025. DOI: https://doi.org/10.1016/j.fertnstert.2023.07.025
Strauss JF, Barbieri RL, Dokras A, Williams CJ, Williams SZ, editors. Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management [Internet]. 9th ed. Philadelphia: Elsevier; 2023 [cited 2026 Aug 27]. Available from: ClinicalKey, https://www.clinicalkey.com.
Ee C, Tay CT. Pharmacological management of polycystic ovary syndrome. Aust Prescr. 2024;47(4):109-112. doi:10.18773/AUSTPRESCR.2024.030. DOI: https://doi.org/10.18773/austprescr.2024.030
Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(2):e817-e836. doi:10.1210/clinem/dgad465. DOI: https://doi.org/10.1210/clinem/dgad465
Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, et al. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023;63:102162. doi:10.1016/j.eclinm.2023.102162. DOI: https://doi.org/10.1016/j.eclinm.2023.102162
Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704. doi:10.1111/obr.13704. DOI: https://doi.org/10.1111/obr.13704
Forslund M, Melin J, Stener-Victorin E, Teede H, Vanky E, Piltonen T. International evidence-based guideline on assessment and management of PCOS: a Nordic perspective. Acta Obstet Gynecol Scand. 2024;103(1):7-12. doi:10.1111/aogs.14725. DOI: https://doi.org/10.1111/aogs.14725